Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi Awarded 2025 Nobel Prize in Medicine for Pioneering Work on Immune Tolerance
STOCKHOLM, October 6, 2025 — The Nobel Assembly at the Karolinska Institutet announced today that the 2025 Nobel Prize in Physiology or Medicine has been awarded jointly to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their discoveries concerning peripheral immune tolerance. Their collective research has transformed the global understanding of how the human body maintains immune balance and prevents autoimmune diseases, offering new hope for therapies that could revolutionize medicine in the 21st century.
The Foundation of Immune Tolerance
The concept of immune tolerance — the body’s ability to distinguish between self and non-self — lies at the heart of immunology. When this vital mechanism falters, the immune system can mistakenly attack its own tissues, resulting in conditions such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, or lupus. The discoveries honored by the 2025 Nobel Prize illuminate the precise biological pathways that keep such destructive responses in check.
Dr. Shimon Sakaguchi, a Japanese immunologist, was the first to identify a specialized subset of immune cells — regulatory T cells, or Tregs — in the 1990s. His work demonstrated that these cells played a crucial role in maintaining immune tolerance. Without them, the immune system could spiral into uncontrolled self-destruction. Sakaguchi’s pioneering research opened the door to an entirely new field of study that continues to influence treatments for autoimmune disorders and organ transplantation.
Years later, American scientists Mary E. Brunkow and Fred Ramsdell extended those findings through the discovery of the FOXP3 gene, a genetic master switch for regulatory T cell development. Their early 2000s work elucidated how mutations in FOXP3 lead to severe autoimmune diseases, such as IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, X-linked). By connecting Sakaguchi’s cellular discoveries to this genetic mechanism, Brunkow and Ramsdell provided a molecular foundation for understanding immune regulation.
A Cross-Continental Collaboration
Though their most significant contributions originated from separate institutions and timelines, the work of Sakaguchi, Brunkow, and Ramsdell converged in remarkable harmony. Sakaguchi, at Osaka University and later Kyoto University, focused on defining the biological characteristics of regulatory T cells. Meanwhile, Brunkow and Ramsdell — both prominent figures in U.S. biotechnology research — identified and cloned FOXP3 through genetic studies in mice that mirrored autoimmune symptoms seen in humans.
This cross-continental convergence between genetic discovery and cellular biology is a hallmark of modern biomedical science. By bridging molecular genetics and immunological function, their research laid the groundwork for the possibility of controlling immune tolerance through therapeutic intervention. It remains a model for how independent scientific threads can intertwine to transform medical understanding.
From Bench to Bedside: The Medical Impact
The real-world ramifications of these discoveries extend far beyond theoretical immunology. Regulatory T cell biology now underpins many clinical research programs aimed at restoring immune balance. In practice, this means designing treatments that can selectively activate or suppress certain immune functions.
Autoimmune diseases, which affect an estimated 4–5% of the global population, are particularly poised to benefit. The insight that the immune system can be “re-educated” to tolerate the body’s own tissues has already led to promising therapies, including Treg cell infusions, gene therapies to modulate FOXP3 expression, and biologic drugs designed to strengthen tolerance pathways without compromising pathogen defense. These therapeutic strategies are being explored in Europe, the United States, and Asia, underscoring the truly global significance of this year’s Nobel-winning research.
Moreover, advances inspired by these discoveries have also transformed transplant medicine. Achieving immune tolerance between donor and recipient tissues remains a core challenge in organ transplantation. The precise manipulation of regulatory T cells, guided by the molecular blueprint uncovered by Brunkow, Ramsdell, and Sakaguchi, is helping researchers devise methods to reduce the need for lifelong immunosuppressive drugs — drugs that, while effective, often leave patients vulnerable to infection and cancer.
Historical Context and Legacy
The history of the Nobel Prize in Physiology or Medicine is rich with awards recognizing the immune system’s complexity. From Jules Bordet’s 1919 prize for immunity studies to the 2018 award honoring CTLA-4 and PD-1 checkpoint research, immunology has been a recurring focal point in Nobel history. Yet, the 2025 recognition of peripheral immune tolerance marks a particularly profound moment: it highlights not only the elegance of immune cooperation but also how the precise failure of such balance can devastate the body.
In the decades following Sakaguchi’s initial identification of regulatory T cells, the field of immunoregulation has exploded. Laboratories worldwide have mapped signaling pathways, cytokine interactions, and genetic networks that define tolerance. The discoveries laid down by these three laureates have been cited in thousands of peer-reviewed publications, influencing research in cancer immunotherapy, allergy treatment, and even neurodegenerative disease.
Economic and Global Health Impact
The economic implications of immune tolerance research extend across biotechnology, pharmaceuticals, and healthcare systems globally. The autoimmune disease diagnostics and therapeutics market, valued at over $120 billion in 2024, continues to expand as biotech companies race to develop treatments that correct immune imbalances at their source. Regulatory T cell–based therapies, now in various stages of clinical testing, are projected to represent a multi-billion-dollar sector by the early 2030s.
In Japan, Sakaguchi’s discoveries spurred public and private investment in immunology research hubs, contributing to the country’s biomedical innovation ecosystem. In the United States, biotechnology firms founded or influenced by Brunkow and Ramsdell’s work have created long-term economic value and high-skill jobs, particularly in Pacific Northwest research corridors. Meanwhile, European pharmaceutical initiatives — including collaborative programs at the Karolinska Institutet — continue to harness these insights to improve autoimmune disease treatment accessibility across the region.
Public health experts argue that long-term mastery of immune tolerance could dramatically reduce global healthcare costs by decreasing lifetime treatment burdens for chronic autoimmune conditions, which are among the most resource-intensive diseases in modern medicine.
The Announcement and Global Reaction
At the Karolinska Institutet’s press conference in Stockholm, the Nobel Assembly delivered the announcement to a crowd of journalists, scientists, and healthcare professionals. The laureates, reached separately by phone, expressed surprise and gratitude. Dr. Sakaguchi, speaking from Kyoto, described the moment as “deeply humbling,” emphasizing the collaborative nature of scientific discovery. Ramsdell and Brunkow, contacted in the United States, echoed the sentiment, dedicating the prize to decades of teamwork across disciplines.
Across social media and academic circles, the response was immediate. Immunologists hailed the recognition as a “historic correction,” long overdue for discoveries that have transformed everyday biomedical practice. Alumni from institutions including Kyoto University, the Karolinska Institutet, and various U.S. biotech firms shared photos and tributes celebrating the announcement.
Major global health organizations, including the World Health Organization and the National Institutes of Health, released statements noting that the recognition underscores the importance of long-term basic research. Decades-old questions about how the immune system distinguishes friend from foe have led directly to targeted treatments capable of saving lives, a progression that symbolizes the enduring value of scientific persistence.
Looking Ahead: The Future of Immune Research
The Nobel recognition of peripheral immune tolerance marks an inflection point in modern medicine. Research is shifting from suppressing the immune system broadly — as with steroids or immunosuppressants — to tuning its subtle internal regulators. By decoding how regulatory T cells function, scientists are now exploring precision methods to recalibrate tolerance and immunity with surgical accuracy.
Emerging therapies include reprogramming patient-derived T cells, developing small molecules that enhance Treg stability, and exploring gene-editing techniques targeting FOXP3 pathways to prevent autoimmune onset in high-risk individuals. Clinical trials across Europe, Asia, and North America are accelerating these applications, building directly on the enduring legacy of this year’s Nobel laureates.
As this new chapter unfolds, the names Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi will resonate not only within the annals of Nobel history but across the broader narrative of human health. Their discoveries have illuminated the delicate orchestration that keeps the immune system aligned with life itself — a subtle, powerful balance that science continues to uncover.